Displaying 1–25 of 28 results for Baxter BioPharma
Pharma Stays on Track. Respondents to our 13th annual Career and Salary Survey find stability and satisfaction despite increased workloads and changing market conditions.
Once biopharma companies optimize operations in order to free up hidden capacity, they have four options: build, acquire, partner or face the realities of outsourcing
Many new facilities are designed for flexibility, combined with low-cost, highly efficient manufacturing
Gaining both mass and velocity, Biopharma is an industry on the move
Plans are underway for Baxter's global innovation and research and development (R&D) center in Cambridge, Mass.
Leveraging the very latest in bioprocessing technology and plant and process design, Baxter’s new Covington, Ga., facility and DSM’s cGMP facility in Brisbane, Australia, represent the state-of-the-art in pharma manufacturing.
Clearly articulating its long-term strategic and global interest in biologics, last October DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, officially announced opening of its new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, ...
"OUS" companies are enjoying the U.S. market, and creating a few jobs along the way.
Using empirical, or science-based, freeze-drying approaches versus trial and error can help you navigate potential commercialization roadblocks.
Clearly worded contracts are essential, wherever your contract partner is based. Dr. Eize de Boer of SGS spells out the requirements.
Pharmaceutical Manufacturing has always covered contract manufacturers in depth, both in print and online. We base these articles on first-hand information, an interview and a plant visit, or invitre a technical expert within the company to collaborate on a piece with an expert within the drug ...
Innovation is shortening time to market, reducing capacity requirements and improving yields
Technology transfer was once taken for granted as something that would get done anyway. Now its an indicator of manufacturing excellence and a core competency for drug innovators.
Manufacturers are ramping up liquid and lyophilization capabilities and adding specialized services.
Editor in Chief Agnes Shanley recaps the highlights of Interphex 2006.
Process Analytical Technology: Weak FDA support and a dearth of adequate sensor technology are holding back adoption of PAT in biopharmaceutical manufacturing, says Xcellerex President Galliher.
The Lean and Six Sigma library offers a focused, easy-to-search source of case histories and best practices that pharma and biopharma companies are using to improve their manufacturing operations and supply chain agility. It also features benchmarking studies from other industries that can be ...